Moderna is scaling down its investments in vaccine development as the U.S. market grows increasingly hostile to immunizations, CEO Stéphane Bancel told Bloomberg News at the World Economic Forum in Davos, Switzerland.
“You cannot make a return on investment if you don’t have access to the U.S. market,” Bancel told Bloomberg, noting that high-level headwinds have made the vaccine market “much smaller.” In particular, the CEO pointed to regulatory roadblocks and diminishing support from health authorities as key problems for Moderna and the vaccine space more broadly.
Moving forward, Bancel told Bloomberg that Moderna will no longer put money into late-stage vaccine studies, though it remains unclear if the CEO was speaking of all vaccines or just those for infectious diseases.
[...]
Bancel joins Pfizer CEO Albert Bourla in criticizing Kennedy and his “anti-science” policies. Also at Davos, Bourla earlier this week referred to HHS’ vaccine policies as “almost like a religion.”
Moderna, which has weathered successive quarters of declining earnings, has been heavily affected by these policy headwinds. In May, the company withdrew the approval application for its combination vaccine for flu and COVID-19. Weeks later, Moderna lost a government bird flu contract potentially worth more than $760 million after HHS terminated the project.
From the article:
[...]
These anti science fascists are going to be the death of us.